Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registration Statesort icon
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II 2010-12-17 Registered
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. 2010-12-17 Registered
Use of h-R3 monoclonal antibody and radiotherapy to treat patients with advanced epithelial head and neck tumors. 2010-12-17 Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors 2013-06-19 Registered
EGF vaccine- Advanced Lung tumors 2013-06-20 Registered
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS) 03/03/2023 Registered
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I 03/11/2017 Registered
Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors 17/02/2017 Registered
14F7 in chronic B-cell lymphoproliferative syndrome 07/03/2018 Registered
EC122 HER-1 Prostate Phase I 15/11/2016 Registered
NGcGM3/VSSP in Metastatic melanoma 07/12/2016 Registered
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. 23/05/2014 Registered
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer 12/10/2016 Registered
hR3 in metastatic or recurrent colorectal cancer 22/11/2013 Registered
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. 26/05/2014 Registered
CIMAVax EGF in Lung Cancer in PHC. Phase IV 05/08/2014 Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis 22/05/2015 Registered
Predictor of response with CIMAvax EGF© in NSCLC Phase III 29/01/2016 Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 08/10/2015 Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus 23/12/2016 Registered